Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 1 — Acute Myeloid Leukemia

> Tuesday, March 16, 2021 5:00 PM – 6:00 PM ET

Faculty Rhonda Hewitt, MSN, ANP, AOCNP Mark Levis, MD, PhD



Faculty



Rhonda Hewitt, MSN, ANP, AOCNP Hematology Advanced Practice Provider Stanford Health Care Palo Alto, California



Mark Levis, MD, PhD Director, Adult Leukemia Program Co-Division Director, Hematologic Malignancies Professor of Oncology The Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine Baltimore, Maryland



Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.



Dr Love — Disclosures

Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME and NCPD activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies Corporation, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Guardant Health, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seagen Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Verastem Inc.



Research To Practice CME Planning Committee Members, Staff and Reviewers

Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.



Ms Hewitt — Disclosures

No relevant conflicts of interest to disclose




Dr Levis — Disclosures

Advisory Committee	AbbVie Inc, Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc, Menarini Group, Takeda Oncology
Contracted Research	Astellas, FUJIFILM Pharmaceuticals USA Inc




We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.



Familiarizing Yourself with the Zoom Interface How to answer poll questions



When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.



ONCOLOGY TODAY WITH DR NEIL LOVE

ACUTE MYELOID LEUKEMIA WITH FLT3 MUTATIONS



DR KEITH PRATZ UNIVERSITY OF PENNSYLVANIA







Dr Keith Pratz Acute Myeloid Leukemia Oncology Today with Dr Neil Love —

(15) (30)

Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

> Wednesday, March 17, 2021 5:00 PM – 6:00 PM ET

> > Faculty Alan P Venook, MD



Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 2 — HER2-Positive Breast Cancer

> Thursday, March 18, 2021 5:00 PM – 6:00 PM ET

Faculty Jamie Carroll, APRN, MSN, CNP Sara Hurvitz, MD



Cases from the Community: Investigators Discuss the Role of PARP Inhibition in the Care of Actual Patients with Ovarian Cancer

> Saturday, March 20, 2021 4:00 PM – 5:00 PM ET

Faculty

Susana Banerjee, MBBS, MA, PhD Richard T Penson, MD, MRCP Shannon N Westin, MD, MPH



Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma

Thursday, March 25, 2021 5:00 PM – 6:00 PM ET

> Faculty Robert J Motzer, MD



Meet The Professor Management of Chronic Lymphocytic Leukemia

Monday, March 29, 2021 5:00 PM – 6:00 PM ET

Faculty Philip A Thompson, MB, BS



Meet The Professor Immunotherapy and Novel Agents in Gynecologic Cancers

> Monday, April 5, 2021 5:00 PM – 6:00 PM ET

Faculty Bradley J Monk, MD



Thank you for joining us!

NCPD credit information will be emailed to each participant within 3 business days.



Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 1 — Acute Myeloid Leukemia

> Tuesday, March 16, 2021 5:00 PM – 6:00 PM ET

Faculty Rhonda Hewitt, MSN, ANP, AOCNP Mark Levis, MD, PhD



Faculty




Rhonda Hewitt, MSN, ANP, AOCNP Hematology Advanced Practice Provider Stanford Health Care Palo Alto, California



Mark Levis, MD, PhD Director, Adult Leukemia Program Co-Division Director, Hematologic Malignancies Professor of Oncology The Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Medicine Baltimore, Maryland




We Encourage Clinicians in Practice to Submit Questions



Feel free to submit questions now before the program begins and throughout the program.



Familiarizing Yourself with the Zoom Interface How to answer poll questions



When a poll question pops up, click your answer choice from the available options. Results will be shown after everyone has answered.



ONCOLOGY TODAY WITH DR NEIL LOVE

ACUTE MYELOID LEUKEMIA WITH FLT3 MUTATIONS



DR KEITH PRATZ UNIVERSITY OF PENNSYLVANIA







Dr Keith Pratz Acute Myeloid Leukemia Oncology Today with Dr Neil Love —

(15) (30)

Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

> Wednesday, March 17, 2021 5:00 PM – 6:00 PM ET

> > Faculty Alan P Venook, MD



Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 2 — HER2-Positive Breast Cancer

> Thursday, March 18, 2021 5:00 PM – 6:00 PM ET

Faculty Jamie Carroll, APRN, MSN, CNP Sara Hurvitz, MD



Cases from the Community: Investigators Discuss the Role of PARP Inhibition in the Care of Actual Patients with Ovarian Cancer

> Saturday, March 20, 2021 4:00 PM – 5:00 PM ET

Faculty

Susana Banerjee, MBBS, MA, PhD Richard T Penson, MD, MRCP Shannon N Westin, MD, MPH



Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Renal Cell Carcinoma

Thursday, March 25, 2021 5:00 PM – 6:00 PM ET

> Faculty Robert J Motzer, MD



Meet The Professor Management of Chronic Lymphocytic Leukemia

Monday, March 29, 2021 5:00 PM – 6:00 PM ET

Faculty Philip A Thompson, MB, BS



Meet The Professor Immunotherapy and Novel Agents in Gynecologic Cancers

> Monday, April 5, 2021 5:00 PM – 6:00 PM ET

Faculty Bradley J Monk, MD



Dissecting the Decision: Clinical and Nursing Investigators Provide Practical Perspectives on Key Issues in Cancer Care Part 1 — Acute Myeloid Leukemia

> Tuesday, March 16, 2021 5:00 PM – 6:00 PM ET

Faculty Rhonda Hewitt, MSN, ANP, AOCNP Mark Levis, MD, PhD



Agenda

Case Presentation: Ms Hewitt — An 81-year-old man with newly diagnosed poor-risk AML

Module 1: Molecular Evaluation of Patients with Newly Diagnosed AML

Module 2: Venetoclax Combinations; Management of Tumor Lysis Syndrome

Case Presentation: Dr Levis — An 82-year-old man with AML and a FLT3 ITD mutation

Module 3: Management of AML with FLT3 Mutation

Module 4: Management of AML with IDH Mutation

Module 5: Other Novel Agents and Strategies



Agenda

Case Presentation: Ms Hewitt — An 81-year-old man with newly diagnosed poor-risk AML

Module 1: Molecular Evaluation of Patients with Newly Diagnosed AML

Module 2: Venetoclax Combinations; Management of Tumor Lysis Syndrome

Case Presentation: Dr Levis — An 82-year-old man with AML and a FLT3 ITD mutation

Module 3: Management of AML with FLT3 Mutation

Module 4: Management of AML with IDH Mutation

Module 5: Other Novel Agents and Strategies



Research To Practice First Annual Oncology Nursing Retreat

Friday, November 8, 2019

Moderator Neil Love, MD

Keynote Panel: AML Rhonda Hewitt, MSN, RN, ANP-BC, AOCNP Daniel A Pollyea, MD, MS Eytan M Stein, MD Lauren Ziskind, APN, NP-C, OCN







"Completely game changing. I mean, I like to say the outpatient management of AML almost used to not exist. There was no place for it. You were seeing people in long-term remission or they were in the hospital. So we actually have an AML clinic now and it's a place where instead of having end-of-life discussions and talking about hospice and goals of care, you're talking about the future and their 38 grandchildren and their vacation. So it's completely changed everything."

Daniel A Pollyea, MD, MS







- 81 yo man with poor-risk AML (complex karyotype & p53/TET2 mutations) presents with his wife & 2 adult children to Hematology Clinic to discuss options for his newly diagnosed AML
- HPI Summary
 - 5.5 yr h/o mild thrombocytopenia
 - Increasing fatigue & SOBOE over past month
 - PCP orders fatigue w/u with CBCD, thyroid studies, iron studies
 - CBCD with pancytopenia
 - BMBx reveals AML evolving from MDS





- Impression/Plan
 - Poor-risk AML (complex karyotype & p53/TET2 mutations)
 - We discussed the diagnosis, natural history, prognosis, & treatment of AML
 - We discussed that AML is an incurable, life threatening, aggressive disease
 - We explained that our goal would be to control the disease the best we can
 - We explained that high-dose chemotherapy would not be an option given his age & comorbidities
 - Treatment options included low-intensity therapy with HMA/venetoclax, clinical trial, supportive care





- Important to patient & his family
 - Patient feels he is still contributing to society
 - Wants to continue to work as CPA
 - Not ready for/interested in supportive care only option
 - Not interested in clinical trial as it would necessitate he receive therapy at a different medical center which is farther from home
 - Prefers the "known" expected responses & SEs with SOC decitabine + venetoclax
 - Hoping to maintain his active lifestyle including hobby of bridge photography for which he has an upcoming trip planned





- He decides to proceed with decitabine + venetoclax
- When starting a patient on therapy we educate about potential SE's
 - Cytopenias requiring transfusion support & dose adjustments/interruptions
 - Risk of life threatening infections +/- bleeding complications
 - Fatigue from therapy
 - GI toxicities
 - Need to protect & monitor for TLS, AKI, other organ toxicities
 - Medication adherence with oral therapies
- Patients generally get a little sicker before they get better → unique to our area of medicine
- I also like to stress the importance of communication, open dialogue so we can help get patients through therapy







- 6/6/19 C1D1 5-day decitabine + venetoclax. Complicated by prolonged neutropenia
- 7/1/19 BMBx no morphologic evidence of leukemia, 0.2% abnormal blasts by MRD flow consistent with morphologic leukemia-free state
- 7/3/19 C2D1 Dec/Ven with 25% dose reduction due to cytopenias & MLFS
 - \rightarrow received only 3 days due to neutropenic fever hospitalization
- 8/1/19 C3D1 dose reduced Dec + Ven
- 9/5/19 C4D1 with further dose reduction due to recurrent neutropenia → Dec 5 to 4 days & Ven 28 to 14 days





Key management points with patient & family:

- Balancing disease control and toxicities of therapy
 - Fatigue, nausea, myelosuppression, RLE cellulitis
- Much support through necessary dose reductions
 - Ongoing discussions re cause of myelosuppression → therapy vs disease progression
 - Possible BMBx if persists/worsens
 - Education/scheduling of labs & transfusion support
- Education on neutropenia & reportable symptoms/problems
- Maintaining roles while undergoing therapy → very important to patient to continue to work part time
- Ongoing participation in important life events

 patient has upcoming vacation plans to go on a photography trip. C5D1 delayed to accommodate this important event



Agenda

Case Presentation: Ms Hewitt — An 81-year-old man with newly diagnosed poor-risk AML

Module 1: Molecular Evaluation of Patients with Newly Diagnosed AML

Module 2: Venetoclax Combinations; Management of Tumor Lysis Syndrome

Case Presentation: Dr Levis — An 82-year-old man with AML and a FLT3 ITD mutation

Module 3: Management of AML with FLT3 Mutation

Module 4: Management of AML with IDH Mutation


Module 5: Other Novel Agents and Strategies




Interpreting Bone Marrow Biopsy Tests



Into a murky world....





First pull:



marrow aspirate









Courtesy of Mark Levis, MD, PhD


What do we get when the procedure is over?

- A small cylinder of bone...
- A few glass coverslips with marrow aspirate...
- Vacutainer tubes with marrow aspirate...
- An angry/frightened/oversedated patient...
- The bone marrow tech shaking their head as they push the cart out of the room.






Core Biopsy:



Cellular or Hypercellular Hypocellular




The core biopsy sample is used to estimate the cellularity of the marrow.






Hypercellular (i.e., packed) Hypocellular (i.e., empty)

Next: Flow cytometry




The entire process takes 1-2 hours...


What do we do with the aspirate slides?




Good!








- Visually inspect the aspirate to make sure it really is bone marrow and not blood.
- Count the number of blasts as a percentage (this is termed a "Differential").
- Compare what you see with the results of the core biopsy and flow cytometry.



Bad...



Three reasons for improvements in survival for AML patients

- Supportive care improved
- Therapy is tailored to fit the patient and the disease
- Improvements in allogeneic transplant techniques

Targeted agents to treat AML

- Gemtuzumab ozogamicin
- IDH inhibitors
- FLT3 inhibitors
- Venetoclax
- Glasdegib



Agenda

Case Presentation: Ms Hewitt — An 81-year-old man with newly diagnosed poor-risk AML

Module 1: Molecular Evaluation of Patients with Newly Diagnosed AML

Module 2: Venetoclax Combinations; Management of Tumor Lysis Syndrome

Case Presentation: Dr Levis — An 82-year-old man with AML and a FLT3 ITD mutation

Module 3: Management of AML with FLT3 Mutation

Module 4: Management of AML with IDH Mutation

Module 5: Other Novel Agents and Strategies



Which of the following agents is FDA approved in combination with venetoclax for acute myeloid leukemia (AML)?

- 1. Decitabine
- 2. Azacitidine
- 3. Low-dose cytarabine
- 4. All of the above
- 5. Only 1 and 2
- 6. I don't know



Venetoclax-based combination regimens are currently approved for AML in...

- 1. All patients
- 2. Patients who are not candidates for intensive chemotherapy
- 3. I don't know



All patients with AML who are receiving venetoclax in combination with a hypomethylating agent should be admitted to the hospital to begin treatment and receive tumor lysis syndrome prophylaxis, regardless of disease burden or performance status.

- 1. Agree
- 2. Disagree
- 3. I don't know




Treating the older acute leukemia patient



Testa di Vecchio; Camillo Boccaccino; 1530

The Reality for Older Patients with AML



Medeiros et al, Ann Hematol 2015

Rationale for BCL-2 Inhibition in AML

- Targeting BCL-2 may allow for apoptosis to be restored
- BCL-2 overexpression associated with worse outcomes in AML, and higher resistance to conventional therapy
- But BCL-2 overexpression not universal in AML


Additional rationale for targeting BCL-2 in AML?

Karakas et al. Annals of Oncology 1998 Lauria et al. Leukemia 1997 Campos et al. Blood 1993 Certo, Letai et al. Cancer Cell 2006



Venetoclax

Venetoclax Mechanism of Action



- Cancer cells increase the expression of anti-apoptotic proteins to offset the increase in pro-apoptotic proteins, tipping the balance toward cell survival
- The large # of pro-apoptotic proteins bound and sequestered by Bcl-2 in AML make them "primed" for death



FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia

Press Release – October 16, 2020

"The Food and Drug Administration granted regular approval to venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy.

Venetoclax was initially granted accelerated approval for this indication in November 2018.

Efficacy was confirmed in two randomized, double-blind, placebo-controlled trials in patients with AML described above.

In VIALE-A (NCT02993523), patients were randomized to receive venetoclax plus azacitidine (n=286) or placebo plus azacitidine (n=145). Efficacy was established based on an improvement in overall survival (OS).

In VIALE-C (NCT03069352), patients were randomized to receive venetoclax plus LDAC (n=143) or placebo plus LDAC (n=68). Efficacy was based on CR rate and duration of CR."

https://www.fda.gov/drugs/drug-approvals-and-databases/fda-grants-regular-approval-venetoclax-combination-untreated-acutemyeloid-leukemia



N Engl J Med 2020;383:617-29.

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

AUGUST 13, 2020


VOL. 383 NO. 7

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

C.D. DiNardo, B.A. Jonas, V. Pullarkat, M.J. Thirman, J.S. Garcia, A.H. Wei, M. Konopleva, H. Döhner, A. Letai, P. Fenaux, E. Koller, V. Havelange, B. Leber, J. Esteve, J. Wang, V. Pejsa, R. Hájek, K. Porkka, Á. Illés, D. Lavie, R.M. Lemoli, K. Yamamoto, S.-S. Yoon, J.-H. Jang, S.-P. Yeh, M. Turgut, W.-J. Hong, Y. Zhou, J. Potluri, and K.W. Pratz




VIALE-A Study Design



(NCT02993523)




VIALE-A: Overall Survival (N = 431)





DiNardo CD et al. N Engl J Med 2020;383:617-29.

VIALE-A: Response Rates (CR + CRi) Subgroups





DiNardo C et al. EHA 2020; Abstract LB2601.

VIALE-A: Selected Key AML Serious Adverse Events

Event	Azacitidine–Venetoclax Group (N=283)		Azacitidine–Placebo Group (N=144)	
	All Grades†	≥Grade 3‡	All Grades†	≥Grade 3‡
	number of patients (percent)			
Serious adverse events§	235 (83)	232 (82)	105 (73)	102 (71)
Febrile neutropenia	84 (30)	84 (30)	15 (10)	15 (10)
Anemia	14 (5)	14 (5)	6 (4)	6 (4)
Neutropenia	13 (5)	13 (5)	3 (2)	3 (2)
Atrial fibrillation	13 (5)	10 (4)	2 (1)	2 (1)
Pneumonia	47 (17)	46 (16)	32 (22)	31 (22)
Sepsis	16 (6)	16 (6)	12 (8)	12 (8)



DiNardo CD et al. *N Engl J Med* 2020;383:617-29.



CLINICAL TRIALS AND OBSERVATIONS

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial


Andrew H. Wei,^{1,2} Pau Montesinos,^{3,4} Vladimir Ivanov,⁵ Courtney D. DiNardo,⁶ Jan Novak,^{7,8} Kamel Laribi,⁹ Inho Kim,¹⁰ Don A. Stevens,¹¹ Walter Fiedler,¹² Maria Pagoni,¹³ Olga Samoilova,¹⁴ Yu Hu,¹⁵ Achilles Anagnostopoulos,¹⁶ Julie Bergeron,¹⁷ Jing-Zhou Hou,¹⁸ Vidhya Murthy,¹⁹ Takahiro Yamauchi,²⁰ Andrew McDonald,²¹ Brenda Chyla,²² Sathej Gopalakrishnan,²² Qi Jiang,²² Wellington Mendes,²² John Hayslip,²² and Panayiotis Panayiotidis²³

Blood 2020;135(24):2137-45.



VIALE-C Phase 3 Study Design

Randomized 2:1, double-blind, placebo-controlled trial




Progressive disease was defined per ELN recommendations.²

AML, acute myeloid leukemia; CR, complete remission; CRh, CR with partial hematologic recovery; CRi, CR with incomplete blood count recovery; EFS, event-free survival; ELN, European LeukemiaNet; IRT, Interactive Response Technology; IWG, International Working Group; LDAC, low-dose cytarabine; MRD, minimal residual disease; OS, overall survival; QD, once a day; ROW, rest of world; SC, subcutaneous. 1. Cheson BD, et al. *J Clin Oncol.* 2003;21:4642-4649; 2. Döhner H, et al. *Blood.* 2017;129:424-447.



VIALE-C: Overall Survival





Wei AH et al. *Blood* 2020;135(24):2137-45.

VIALE-C: Response Rates and Other Efficacy Endpoints

	%		
End point	Placebo + LDAC (n = 68)	Venetoclax + LDAC (n = 143)	Р
Remission rate			
CR*	7 (2-16)	27 (20-35)	<.001
CR/CRi†	13 (6-24)	48 (39-56)	<.001
By initiation of cycle 2	3 (0-10)	34 (27-43)	<.001
CR/CRh‡	15 (7-25)	47 (39-55)	<.001
By initiation of cycle 2	4 (1-12)	31 (23-39)	<.001
Other			
EFS, mo			.002
Median	2.0	4.7§	
95% CI	1.6-3.1	3.7-6.4	
Transfusion independence			
Red blood cells	18 (10-29)	41 (32-49)	.001
Platelets	32 (22-45)	48 (39-56)	.040
Both	16 (8-27)	37 (29-46)	.002



VIALE-C: Selected Key AML Serious Adverse Events

	n (%)		
AE	Placebo + LDAC (n = 68)	Venetoclax + LDAC (n = 142)	
Selected key AML serious AEs			
Febrile neutropenia	12 (18)	23 (16)	
Pneumonia	7 (10)	18 (13)	
Sepsis	4 (6)	8 (6)	
Thrombocytopenia	2 (3)	7 (5)	
Anemia	0	4 (3)	
Neutropenia	0	4 (3)	



Wei AH et al. *Blood* 2020;135(24):2137-45.

Future Directions: Combination Therapies

Low Intensity Triplets

- With other genomically defined targeted therapies
- With other BCL-2 family members

With intensive chemotherapy

- Up front
- Salvage

Future Directions: New Settings

- Older "fit" patients
- Younger "fit" patients
- Relapsed AML
- Maintenance strategies

Agenda

Case Presentation: Ms Hewitt — An 81-year-old man with newly diagnosed poor-risk AML

Module 1: Molecular Evaluation of Patients with Newly Diagnosed AML

Module 2: Venetoclax Combinations; Management of Tumor Lysis Syndrome

Case Presentation: Dr Levis — An 82-year-old man with AML and a FLT3 ITD mutation

Module 3: Management of AML with FLT3 Mutation

Module 4: Management of AML with IDH Mutation

Module 5: Other Novel Agents and Strategies



Gilteritinib has been associated with responses in patients with relapsed/refractory AML and...

- 1. An IDH2 mutation
- 2. A FLT3 mutation
- 3. Myelodysplasia-related changes
- 4. I don't know



Case Presentation – Dr Levis: An 82-year-old man with AML and a FLT3 ITD mutation

Patient Circumstances

- Very fit, British, independent contractor working full time
- Admitted to the hospital emergently in the COVID-19 era
- Contact with spouse and other family members solely via Zoom, telephone

Clinical Presentation and Treatment Course

- 6/2020 Presents to urgent care with fatigue: WBC 100,000, PLT 30, Hgb 8 → Emergency room
- Peripheral blood flow to assess for leukostasis, AML
- Hydroxyurea
- Patient mildly hypoxic due to DVT/PE and leukostasis
- Gemtuzumab, with decrease in WBC
- Azacitidine/venetoclax, with dramatic improvement in counts by day 20, hospital release by day 24
- Bone marrow biopsy: morphologic remission but FLT3 detectable, counts normalized
- Switched to azacitidine/gilteritinib
- Currently, back to working full time, with plan to transition to single-agent gilteritinib



Agenda

Case Presentation: Ms Hewitt — An 81-year-old man with newly diagnosed poor-risk AML

Module 1: Molecular Evaluation of Patients with Newly Diagnosed AML

Module 2: Venetoclax Combinations; Management of Tumor Lysis Syndrome


Case Presentation: Dr Levis — An 82-year-old man with AML and a FLT3 ITD mutation

Module 3: Management of AML with FLT3 Mutation

Module 4: Management of AML with IDH Mutation


Module 5: Other Novel Agents and Strategies





Courtesy of Mark Levis, MD, PhD

FLT3 Mutations in AML



Litzow MR. *Blood* 2005;106:3331-2; Small D. *Hematology Am Soc Hematol Educ Program* 2006:178-84; Swords R et al. *Leukemia* 2012;26(10):2176-85; Griffith J et al. *Mol Cell* 2004;13(2):169-78; Levis M. *Hematology Am Soc Hematol Educ Program* 2013;2013:220-6.

Midostaurin

Mechanism of action:

• A multitargeted inhibitor of FLT3


Indication:

 For the treatment of patients with newly diagnosed AML that is FLT3 mutationpositive, as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation.

Recommended dose:

 50 mg twice daily on days 8 to 21 of each cycle of induction and consolidation chemotherapy followed by 50 mg as a single agent for up to 12 months. Administer with food.

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm555756.htm Midostaurin package insert, April 2017 Midostaurin prolongs survival for patients with newly diagnosed FLT3-mutant AML when added to induction chemotherapy




- 5 year survival rate:
 - Midostuarin 50.9% vs. Placebo 43.3%

Courtesy of Mark Levis, MD, PhD

Stone et al. N Engl J Med. 2017; 377:454

Gilteritinib – Phase III ADMIRAL Study




• Based on data from the ongoing ADMIRAL study, gilteritinib is approved in Japan and US for treatment of adults with *FLT3*-mutated R/R AML



1884

Courtesy of Eytan M Stein, MD

ADMIRAL: Overall Survival (ITT Population, N = 371)



Memorial Sloan Kettering Cancer Center

1884

Courtesy of Eytan M Stein, MD

Perl A, et al, NEJM, Oct 31, 2019

Relapsed FLT3-ITD AML

- Disease is typically driven by FLT3
 - If FLT3-ITD mutation still present...
 - 50% of patients treated with midostaurin during induction lose FLT3-ITD mutation at relapse
- Monotherapy with gilteritinib = 50% response rate
 - ...but most patients will ultimately succumb
- Combinations are preferable
 - HiDAc + gilteritinib
 - Aza + gilteritinib
 - IDH1/2 inhibitor + gilteritinib

Agenda

Case Presentation: Ms Hewitt — An 81-year-old man with newly diagnosed poor-risk AML

Module 1: Molecular Evaluation of Patients with Newly Diagnosed AML

Module 2: Venetoclax Combinations; Management of Tumor Lysis Syndrome

Case Presentation: Dr Levis — An 82-year-old man with AML and a FLT3 ITD mutation

Module 3: Management of AML with FLT3 Mutation

Module 4: Management of AML with IDH Mutation

Module 5: Other Novel Agents and Strategies





IDH mutations citrate isocitrate Wild type 10-15% of AML • homodimer Result in the generation of • an "onco-metabolite (IDH1) IDN1 2 hydroxyglutarate (2-HG) **IDH1** mutations • – R132 ol-keto-**IDH2** mutations • glutarate - R140 – R172 **Co-substrate** for dioxygenases, other enzymes.

Mutant heterodimer SHAM IDH1 ZIDHT 2-hydroxyglutarate **Metabolic** chaos Courtesy of Mark Levis, MD, PhD

IDH in Leukemia

- IDH mutations occur in ~20% of AML
 - Frequency: 6%-16% IDH1 and 8%-18% IDH2
 - Majority (85%) with diploid or
 +8 cytogenetics
 - $-\uparrow$ prevalence with \uparrow patient age
 - Prognostic effect in AML remains controversial
 - IDH1 and IDH2 mutations may have different effects on prognosis





Dang L et al. *Trends Mol Med* 2010;16(9):387-97. Chou WC et al. *Leukemia* 2011;25(2):246-53. Patel JP et al. *N Engl J Med* 2012;366(2):1079-89. Medeiros BC et al. *Leukemia* 2017;31:272-81.

IDH2m and IDH1m: Distinct Genetically Defined Populations

	IDH Mutations Seen in Multiple Cancer Types	
Target	Indication	IDHm (%)
IDH2m	AML	15%
	MDS/MPN	5%
	Angio-immunoblastic NHL	25%
	Others (melanoma, glioma, chondro) ²	3-5%
	Type II D-2HG Aciduria (inborn error of metabolism)	100%
IDH1m	Low-grade glioma & 2 ^{ary} GBM ¹	70%
	Chondrosarcoma	>50%
	AML	7.5%
	MDS/MPN	5%
	Intrahepatic cholangiocarcinoma	20%
	Others (colon, melanoma, lung) ²	1-2%



Memorial Sloan Kettering

Courtesy of Eytan M Stein, MD

¹Includes 8.5% of Primary GBM

²Includes "basket" of emerging unconfirmed indications

Approved IDH Inhibitors in AML

- Enasidenib IDH2 inhibitor. Approved for relapsed and refractory IDH2 mutant AML.
 - Oral, given once daily, continuous 28 day cycles
 - Indirect hyperbilirubinemia
- Ivosidenib IDH1 inhibitor. Approved for relapsed and refractory and newly diagnosed IDH1 mutant AML.
 - Oral, once daily, continuous 28 day cycles
 - QT prolongation

• In R/R AML, complete remission rates with IDH inhibitors is about 21%



Differentiation Syndrome

Frequency of Signs and Symptoms	Consistent With IDH-DS ^a
---------------------------------	-------------------------------------

Sign or Symptom	Patients With IDH-DS, No. (%) (n = 33) ^b
Dyspnea	28 (85)
Unexplained fever (body temperature of 38.0°C for 2 d)	26 (79)
Pulmonary infiltrates	24 (73)
Нурохіа	19 (58)
Acute kidney injury (CTCAE grade ≥2)	14 (42)
Pleural effusion	14 (42)
Bone pain or arthralgia	9 (27)
Lymphadenopathy	8 (24)
Rash	8 (24)
Disseminated intravascular coagulopathy	7 (21)
Edema or weight gain of >5 kg from screening	7 (21)
Pericardial effusion	5 (15)


^a Signs and symptoms are based on retrospective differentiation syndrome review committee review of clinical records.

^b Patients may have had multiple symptoms.

Fathi A et al, JAMA Oncology 2018



Management of IDH-DS



*Main symptoms and signs: Dyspnea, fever, rash, pulmonary infiltrates, pleural effusion, renal dysfunction.
**With other supportive measures: -Broad spectrum antibiotics for possible underlying infection. -Cytoreductive therapy if leukocytosis. -Hyperuricemia management if tumor lysis syndrome.
***Symptoms will last several days until improvement due the long halflife of enasidenib.

DS: Differentiation syndrome



Memorial Sloan Kettering Cancer Center Abou Dalle I et al, Ther Adv Heme 2018

Courtesy of Eytan M Stein, MD

Case Presentation – Dr Levis: A 78-year-old man with AML and an IDH1 mutation

Patient Circumstances

- Worked for US government agency, traveled the world
- Supportive wife
- Has not seen grandchildren in the past year due to COVID-19 pandemic

Clinical Presentation and Treatment Course

- Essential thrombocythemia for years \rightarrow transfusion-dependent MDS
- Azacitidine x 4
- 12/2017: Bone marrow transplant
- 12/2018: AML, with IDH1 mutation
- Ivosidenib, with CR but remains transfusion-dependent (every 2 weeks)
- 10/2018 and 12/2018: Added azacitidine to ivosidenib
 - Counts worsened, neutrophils dropped to zero, skin infection \rightarrow meropenem antibiotics
 - Discontinued antibiotic → Counts normalized, Hgb: 13.6, PLT > 100, transfusion not required past 6 months



Agenda

Case Presentation: Ms Hewitt — An 81-year-old man with newly diagnosed poor-risk AML

Module 1: Molecular Evaluation of Patients with Newly Diagnosed AML

Module 2: Venetoclax Combinations; Management of Tumor Lysis Syndrome

Case Presentation: Dr Levis — An 82-year-old man with AML and a FLT3 ITD mutation

Module 3: Management of AML with FLT3 Mutation

Module 4: Management of AML with IDH Mutation

Module 5: Other Novel Agents and Strategies



CPX-351 (liposomal cytarabine-daunorubicin) is approved for...

- 1. AML with a FLT3 mutation
- 2. Secondary AML
- 3. CD33-positive AML
- 4. I don't know




Secondary AML:

AML evolving out of myelodysplasia or a myeloproliferative disorder

- Antecedent hematologic disorder (e.g., MDS or MPN)
 - Often, patient has a history of unexplained anemia or thrombocytopenia
 - Can be diagnosed when patient presents with AML: "AML with trilineage dysplasia"
 - Patient may have 2-3 year h/o MDS, treated with various agents
 - Patient might have h/o Polycythemia Vera, etc...
- Increasing age (a continuous variable)
 - Age usually > 65
 - Usually a different spectrum of mutations compared to AML lacking an antecedent hematologic disorder
 - Outcomes poor

Liposomal Daunorubicin and Cytarabine (CPX-351)



- 1:5 molar ratio of daunorubicin to cytarabine
- Synergistic activity in both in vitro and animal models
- 100 nm bilamellar liposomes
- 1 unit = 0.44 mg daunorubicin and 1.0 mg cytarabine (1:5 molar ratio) complexed with copper
- Targets bone marrow and preferentially targets leukemic compared to normal marrow progenitors

CPX-351

Mechanism of action:

• Liposome-encapsulated fixed ratio of daunorubicin and cytarabine

Indication:


 For the treatment of newly diagnosed therapy-related AML or AML with myelodysplasia-related changes

Recommended dose:

- Induction: (daunorubicin 44 mg/m² and cytarabine 100 mg/m²) liposome via intravenous infusion over 90 minutes on days 1, 3, and 5 and on days 1 and 3 for subsequent cycles of induction, if needed
- Consolidation: (daunorubicin 29 mg/m² and cytarabine 65 mg/m²) liposome via intravenous infusion over 90 minutes on days 1 and 3

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm569950.htm (Daunorubicin and cytarabine) liposome package insert, April 2017

CPX-351 in Secondary AML



Lancet JE et al. ASCO 2011; Abstract 6519.

Case Presentation – Dr Levis: A 78-year-old woman with secondary AML

Patient Circumstances

- Recreational tomato farmer
- Prior history of bladder cancer s/p surgery and chemotherapy 10 years ago
- Recent death (3/2021) of two adult sons in their 50s weeks apart
- COVID-19 pandemic
- National shortage of azacitidine


Clinical Presentation and Treatment Course

- 12/2017 Diagnosed with AML, presumed secondary to prior chemotherapy, with TET2 and NPM1 mutations
- CPX-351, with remission, c/b C. difficile
- 8/2018 Blood counts falling → BMB: TET2, NPM1 readily detectable, blast < 5%
- Subcutaneous azacitidine/venetoclax on outpatient basis, with rapid normalization of counts
 - Substitution of subcutaneous decitabine during shortage



Oral Azacitidine (Oral-AZA, CC-486)

- Oral HMA with a distinct PK/PD profile from injectable AZA; the two are not bioequivalent^{1,2}
- Approved in the United States for continued Tx of adult pts with AML in first CR/CRi post-IC and not able to complete intensive curative therapy (eg, HSCT)³
 - Oral dosing allows for extended drug exposure during each Tx cycle to prolong AZA activity^{1,2}



1. Garcia-Manero et al. J Clin Oncol. 2011;29(18):2521–7. 2. Laille et al. PLoS One. 2015;10(8):e0135520. 3. ONUREG[®] (azacitidine) tablets [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; Rev. 9/2020. 4. Savona et al. Am J Hematol. 2018;93(10):1199–206. 5. Stresemann et al. Mol Cancer Ther. 2008;7:2998–3005. 6. Hollenbach et al. PLoS One. 2010;5(2):e9001. 7. Scott LJ. Drugs. 2016;76(8):889–900. 8. Stresemann C, Lyko F. Int J Cancer. 2008;123(1):8–13. 9. Aimiuwu et al. Blood. 2012;119(22):5229–38.

AML, acute myeloid leukemia; AZA, azacitidine; CR, complete remission; CRi, CR with incomplete blood count recovery; HMA, hypomethylating agent; HSCT, hematopoietic stem cell transplant; IC, intensive chemotherapy; PD, pharmacodynamic; PK, pharmacokinetic; pts, patients; Tx, treatment.



FDA Approves Azacitidine Tablets for Acute Myeloid leukemia Press Release – September 1, 2020

"The Food and Drug Administration approved azacitidine tablets for continued treatment of patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.

Efficacy was investigated in QUAZAR (NCT01757535), a multicenter, randomized, double-blind, placebo-controlled trial. Patients (n=472) who achieved CR or CRi with intensive induction chemotherapy with or without receiving subsequent consolidation therapy were randomized 1:1 to receive azacytidine tablets 300 mg (n=238) or placebo (n=234) orally on days 1 to 14 of each 28-day cycle."



Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission


A.H. Wei, H. Döhner, C. Pocock, P. Montesinos, B. Afanasyev,* H. Dombret,
F. Ravandi, H. Sayar, J.-H. Jang, K. Porkka, D. Selleslag, I. Sandhu, M. Turgut,
V. Giai, Y. Ofran, M. Kizil Çakar, A. Botelho de Sousa, J. Rybka, C. Frairia, L. Borin,
G. Beltrami, J. Čermák, G.J. Ossenkoppele, I. La Torre, B. Skikne, K. Kumar,
Q. Dong, C.L. Beach, and G.J. Roboz, for the QUAZAR AML-001 Trial Investigators⁺

N Engl J Med 2020;383:2526-37.



QUAZAR AML-001: Study Design and Eligibility Criteria

International, multicenter, placebo (PBO)-controlled, double-blind, randomized, phase III study of Oral-AZA as maintenance Tx in pts with AML in first remission post-IC



^aBM aspirates were collected every 3 cycles through cycle 24, at cycle 30 and cycle 36, and as clinically indicated thereafter. BM assessments were also performed as clinically indicated. ^bPatients were followed until death, withdrawal of consent, study termination, or loss to follow-up.

AML, acute myeloid leukemia; ANC, absolute neutrophil count; AZA, azacitidine; BM, bone marrow; CMML, chronic myelomonocytic leukemia; CR, complete remission; CRi, CR with incomplete blood count recovery; ECOG PS, Eastern Cooperative Oncology Group performance status; HRQoL, health-related quality of life; HSCT, hematopoietic stem cell transplant; IC, induction chemotherapy; IWG, International Working Group; MDS, myelodysplastic syndromes; PBO, placebo.



Gemtuzumab Ozogamicin

Mechanism of action:

• Antibody-drug conjugate targeted to CD33

Indication:

• For the treatment of newly diagnosed CD33-positive acute myeloid leukemia (AML) in adults and for the treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older

Recommended dose:


- Newly diagnosed de novo AML (in combination with daunorubicin and cytarabine): 3 mg/m² on days 1, 4 and 7 for induction and 3 mg/m² on day 1 for consolidation
- Newly diagnosed AML (single agent): 6 mg/m² on day 1 and 3 mg/m² on day 8 for induction, followed by up to 8 continuation cycles of 2 mg/m² on day 1 every 4 weeks
- Relapsed or refractory AML (single agent): 3 mg/m² on days 1, 4 and 7

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm574518.htm Gemtuzumab ozogamicin package insert, September 2017

Gemtuzumab Ozogamicin (GO) Antibody-Drug Conjugate: CD33 Antibody Linked to Calicheamicin

History:

- 2000: Granted FDA accelerated approval
- 2010: Voluntarily removed from the market when confirmatory trials did not show a clinical benefit but did show higher chance of death and association with veno-occlusive disease of the liver (VOD)
- 2017: GO received FDA approval in 3 settings, including in combination with induction chemotherapy at a lower dose after review of Phase III results of ALFA 0701 study 1.04




ALFA 0701

- Median EFS: 9.7 vs 15.6 months; *p* = 0.0026
- No difference in OS
- SAEs higher in GO arm

http://www.bloodjournal.org/content/124/21/376?sso-checked=true

Glasdegib

- Oral hedgehog inhibitor
- Minimal single agent activity, but combined with low-dose araC, improved survival
- FDA approved for newly diagnosed AML in patients unfit for intensive therapy



Courtesy of Mark Levis, MD, PhD

The field of AML therapy is rapidly changing...

- Sequencing and stem cell biology studies have advanced our understanding of the disease:
 - "Driver/founder/cooperating" mutations
 - "CHIP"
 - Leukemic stem cells
- New agents added to our arsenal:
 - Midostaurin
 - Liposomal cytarabine and daunorubicin
 - Gemtuzumab ozogamicin
 - Enasidenib
 - Gilteritinib
 - Venetoclax + HMA
 - Glasdegib
- Personalized therapy for AML is here!

Meet The Professor Optimizing the Selection and Sequencing of Therapy for Patients with Advanced Gastrointestinal Cancers

> Wednesday, March 17, 2021 5:00 PM – 6:00 PM ET

> > Faculty Alan P Venook, MD

Moderator Neil Love, MD



Thank you for joining us!

NCPD credit information will be emailed to each participant within 3 business days.

